Canada markets close in 6 hours 24 minutes

Molecular Partners AG (6ML.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
12.900.00 (0.00%)
As of 07:10AM CET. Market open.
Full screen
Previous Close12.90
Open13.58
Bid0.00 x 0
Ask0.00 x 0
Day's Range13.42 - 13.58
52 Week Range12.90 - 13.58
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Molecular Partners Publishes Invitation to Annual General Meeting 2024

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024. The Annual General Meeting will be held on Wednesday, April 17, 2024, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. Invitation to

  • GlobeNewswire

    Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

    Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the ASH Annual Meeting, reporting an acceptable safety profile and initial anti-tumor activityIntroduced the Switch-DARPin concept and platform at PEGS Europe. In January 2024, introduced the first multispecific Switch-DARPin program, targeting cKIT x CD16a x CD47, as a next-generation conditioning regim

  • GlobeNewswire

    Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results. Molecular Partners’ Chief Executive Officer Patrick Amstutz w